Literature DB >> 25806156

Chemotherapy of lung cancer: A global perspective of the role of ifosfamide.

Caicun Zhou1, Christian Manegold2.   

Abstract

The oxazaphosphorine cytostatic ifosfamide (IFO) has been successfully integrated in the treatment of various hematological and solid tumors. The purpose of this review is to summarize the evidence for its use in lung cancer starting from basic data of preclinical studies followed by a global summary of the phase III and seminal phase II clinical studies. Global in double respect: first covering both the small cell as well as the non-small cell indications, and, second tracing those studies performed in Europe and the United States as well as those from Asian countries.

Entities:  

Keywords:  Lung cancer; chemotherapy; ifosfamide

Year:  2012        PMID: 25806156      PMCID: PMC4367585          DOI: 10.3978/j.issn.2218-6751.2011.12.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  62 in total

1.  Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy.

Authors:  Keun-Wook Lee; Yu Jung Kim; Jee Hyun Kim; Soo-Mee Bang; Jin-Haeng Chung; Jong Seok Lee
Journal:  Jpn J Clin Oncol       Date:  2010-10-05       Impact factor: 3.019

2.  Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.

Authors:  A Fujita; H Takabatake; S Tagaki; K Sekine
Journal:  Oncology       Date:  2000-08       Impact factor: 2.935

3.  Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.

Authors:  N H Hanna; A B Sandier; P J Loehrer; R Ansari; S H Jung; K Lane; L H Einhorn
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

4.  [Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

Authors:  Yizhuo Zhao; Yurong Chen; Hao Ji; Tianqing Chu; Baohui Han; Meilin Liao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2004-10-20

5.  Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.

Authors:  Masao Ichiki; Rumi Gohara; Toru Rikimaru; Takao Kitajima; Rei Fujiki; Akiko Shimada; Hisamichi Aizawa
Journal:  Chemotherapy       Date:  2003-07       Impact factor: 2.544

6.  Case report: pulmonary blastoma in children--response to chemotherapy.

Authors:  F Lobo-Sanahuja; I García; S Santamaría; J C Barrantes
Journal:  Med Pediatr Oncol       Date:  1996-03

7.  Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

Authors:  Fariba Némati; Catherine Daniel; Francisco Arvelo; Marie-Emmanuelle Legrier; Benoît Froget; Alain Livartowski; Franck Assayag; Yveline Bourgeois; Marie-France Poupon; Didier Decaudin
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

8.  [Stage IV NSCLC. Place of chemotherapy].

Authors:  A-P Meert
Journal:  Rev Mal Respir       Date:  2008-10       Impact factor: 0.622

9.  Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

Authors:  Sarah Park; Myung Ju Ahn; Jin Seok Ahn; Jeeyun Lee; Yong Sang Hong; Byeong-Bae Park; Sang Chul Lee; In Gyu Hwang; Joon Oh Park; Hoyeong Lim; Won Ki Kang; Keunchil Park
Journal:  Lung Cancer       Date:  2007-07-12       Impact factor: 5.705

10.  A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.

Authors:  Serge Leyvraz; Sandro Pampallona; Giovanni Martinelli; Ferdinand Ploner; Lucien Perey; Savina Aversa; Solange Peters; Paal Brunsvig; Ana Montes; Andrzej Lange; Ugur Yilmaz; Giovanni Rosti
Journal:  J Natl Cancer Inst       Date:  2008-04-08       Impact factor: 13.506

View more
  1 in total

1.  The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.

Authors:  Jun Liu; Xiang Liu; Fei Cui; Guoqin Chen; Yubao Guan; Jianxing He
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.